A Repeated Dose-finding Study of Sarilumab in Children and Adolescents With Systemic Juvenile Idiopathic Arthritis (SKYPS)

NCT02991469 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

51

Enrollment

INDUSTRY

Sponsor class

Conditions

Juvenile Idiopathic Arthritis

Interventions

DRUG: Sarilumab SAR153191 (REGN88)

Sponsor

Sanofi

Collaborators

[object Object]